SLRX (Salarius Pharmaceuticals Inc) Cumulative Company Assets

Official company branding of Salarius Pharmaceuticals Inc (SLRX)

Salarius Pharmaceuticals (SLRX) is currently in the clinical trial stage without a stable cash flow, and its liquidity stands at 4.97. The company is mitigating risks by developing epigenetic therapies to combat rare tumors. This chart of the aggregate asset market price confirms the potential of the business, whose patents for enzyme inhibitors will ensure a prolonged period of exclusivity and sustained demand from medical professionals.

Salarius Pharmaceuticals Inc (SLRX) Aggregate Company Assets: for the period 07/04/2022 - 01/08/2026

Financial and market metric breakdowns for Salarius (SLRX)

- stock quotes and analyst forecast:
Share Price salariuspharma.com|SLRX - Analyst Consensus Forecast
- business market valuation indicators:
Market Valuation Salarius Pharma|SLRX - Enterprise Value
- company book value details:
Book Value per Share Salarius Pharmaceuticals|SLRX - Company Book Value|Capitalization to Book Value Ratio salariuspharma.com|SLRX - Company Total Assets
- debt burden and liquidity indicators:
Total Debt to Equity Ratio Salarius Pharmaceuticals|SLRX - Long-Term Debt to Capital|Current Liabilities to Capital Salarius Pharma|SLRX - Company Debts|Debt to Net Assets Ratio Salarius Pharma|SLRX - Company Long-Term Liabilities|Company Short-Term Loans and Borrowings Salarius Pharmaceuticals|Quick Liquidity Indicator salariuspharma.com
- earnings and market multiples details:
SLRX - Net Income
Basic company analysis:salariuspharma.com (SLRX)
Core merchandise of Salarius Pharmaceuticals, Inc.

Since this metric is calculated inversely via ROA, it reacts sharply to operating profit volatility, measuring the total volume of resources and liabilities to assess financial stability. In the case of Salarius Pharmaceuticals (SLRX), this reflects the ability to maintain complex chemical formula supply chains and the diversification of research bases, which is confirmed through the monitoring of total assets (via ROA).

Key competitors

Total Business Assets ONC|HALO (Halozyme) - Company Total Assets|Cumulative Company Assets Revolution Medicines Inc (RVMD)|Company Total Assets AAPG|Company Total Assets CG Oncology Therapeutics (CGON)|Aggregate Company Assets UroGen Pharma Ltd. URGN|BCAX: Total Business Assets|Personalis - Company Total Assets|Erasca Inc (ERAS) - Cumulative Company Assets|DCTH: Company Total Assets|Company Assets Y-mAbs Corp (YMAB)|Aggregate Company Assets Aura Biosciences, Inc.|CADL: Aggregate Asset Value|Cumulative Company Assets ARAY (Accuray)|SLS (sellaslifesciences.com) - Aggregate Asset Value|Company Total Assets ACTU (Actuate Therapeutics, Inc)|CTOR - Cumulative Company Assets|HURA: Cumulative Company Assets|TARA - Company Total Assets|Fate Therapeutics (FATE) - Aggregate Company Assets|Aadi Bioscience - Aggregate Asset Value|TCRX (TScan Therapeutics Inc) - Company Total Assets|Company Assets Champions Oncology Corp CSBR|Aggregate Company Assets XBiotech Inc. (XBIT)|Company Total Asset Base cel-sci.com|Company Total Assets OSTX (OS Therapies)|Company Total Assets radiopharmtheranostics.com RADX|ARTV - Aggregate Company Assets|ANL: Aggregate Company Assets|VERU: Company Total Assets|tempesttx.com (TPST) - Company Total Assets|Aggregate Company Assets Xilio Therapeutics Inc|RENB: Aggregate Asset Value|Company Total Assets MURA|Company Total Asset Base kairospharma.com|OnKure Therapeutics - Cumulative Company Assets|Company Total Assets CytoMed Therapeutics Ltd GDTC|CRIS - Aggregate Company Assets|Company Total Asset Base Apollomics, Inc. APLM|THAR (Tharimmune Corp) - Cumulative Company Assets|Advanced Biomed - Aggregate Asset Value|Aggregate Company Assets Genprex, Inc.|Calidi Bio - Total Asset Value of Company|Company Total Assets SBFM|XBIO (xeneticbio.com) - Aggregate Asset Value|Company Total Assets PPBT (Purple Biotech Corp)|Company Total Assets American Oncology Network Inc AONC|BGNE - Aggregate Company Assets|Aggregate Asset Value CKPT (checkpointtx.com)|Elevation Oncology (ELEV) - Aggregate Company Assets|Cumulative Company Assets iCAD|IKNA (Ikena Oncology Inc.) - Company Total Assets|Company Total Assets Notable Labs Corp|Company Total Assets VIRX|Cumulative Company Assets morphosys.com MOR|Company Total Assets NAYA (NAYA Biosciences Inc.)|Ascentage Pharma Group International (AAPGV) - Company Assets